Brought to you by 
MannKind brings in $250mm through private placements
04 Oct 2007
Executive Summary
MannKind (therapeutics for cancer and diabetes) raised about $250mm in two private placements. In the first, the company sold 15.9mm common shares at $9.41 apiece (an 8% discount) to its chairman and CEO Alfred Mann for proceeds of $150mm. In the second transaction, Mannkind sold to Legg Mason Capital and other investors of 11mm common shares at $9.03 each (a 5% discount) for proceeds of $100mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Pulmonary
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MannKind brings in $250mm through private placements
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice